Synopsis
Synopsis
0
EU WC
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Eqvalan
2. Ivermectin
3. Ivomec
4. Mectizan
5. Mk 933
6. Mk-933
7. Mk933
8. Stromectol
1. Ivermectin
2. Dihydroavermectin B1a
3. 70288-86-7
4. 22,23-dihydroavermectin B1a
5. 70161-11-4
6. Ivermectin Component B1a
7. 71827-03-7
8. Avermectin H2b1a
9. 5-o-demethyl-22,23-dihydroavermectin A1a
10. Chebi:63941
11. 91y2202ouw
12. (2ae,4e,5's,6s,6'r,7s,8e,11r,13r,15s,17ar,20r,20ar,20bs)-6'-[(2s)-butan-2-yl]-20,20b-dihydroxy-5',6,8,19-tetramethyl-17-oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-tetradecahydro-2h,7h-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacyclooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-o-(2,6-dideoxy-3-o-methyl-alpha-l-arabino-hexopyranosyl)-3-o-methyl-alpha-l-arabino-hexopyranoside
13. Mk-933
14. (1r,4s,5's,6r,6'r,8r,10e,12s,13s,14e,16e,20r,21r,24s)-6'-[(2s)-butan-2-yl]-21,24-dihydroxy-12-[(2r,4s,5s,6s)-5-[(2s,4s,5s,6s)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-5',11,13,22-tetramethylspiro[3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene-6,2'-oxane]-2-one
15. Ivermectin B1a-d2
16. C48h74o14
17. Unii-91y2202ouw
18. 22,23-dihydroavermectin B(1)a
19. Ncgc00163233-01
20. Ivermectin (ivm)
21. Ivm
22. Einecs 276-046-2
23. Dihydro Avermectin Bla
24. Brn 4643153
25. 22,23-dihydro-5-o-demethylavermectin A1a
26. H2b1a
27. Prestwick3_000156
28. Dsstox_cid_3181
29. Ivermectin (mk-0933)
30. Dsstox_rid_76909
31. Dsstox_gsid_23181
32. Bspbio_000292
33. Schembl312795
34. Bpbio1_000322
35. Chembl263291
36. Dtxsid8023181
37. Chebi:94551
38. Hms2089m09
39. Hms2095o14
40. Hms3712o14
41. Wca82703
42. Tox21_112034
43. Bdbm50409816
44. Mfcd30496678
45. S1351
46. Akos027470116
47. Ivermectin Component B1a [mi]
48. Zinc238808778
49. Zinc252286706
50. Ac-6014
51. Ccg-220156
52. Ncgc00186639-01
53. Ncgc00186639-03
54. As-14167
55. Bi166167
56. Cas-71827-03-7
57. Hy-126937
58. Ab00513813
59. Cs-0108408
60. 22,23-dihydroavermectin B1a; Ivermectin
61. Ab00513813-02
62. Ab00513813-03
63. Ab00513813_04
64. Avermectin A1a, 22,23-dihydro-5-o-demethyl-
65. 288i867
66. Ivermectin, Antibiotic For Culture Media Use Only
67. Q-201262
68. Brd-k24652731-001-02-7
69. Brd-k85554912-001-08-9
70. Q27132923
71. Ivermectin, British Pharmacopoeia (bp) Reference Standard
72. Ivermectin, European Pharmacopoeia (ep) Reference Standard
73. Ivermectin, United States Pharmacopeia (usp) Reference Standard
74. Ivermectin, Pharmaceutical Secondary Standard; Certified Reference Material
75. (2ae,4e,5's,6s,6'r,7s,8e,11r,13r,15s,17ar,20r,20ar,20bs)-6'-[(2s)-butan-2-yl]-20,20b-dihydroxy-5',6,8,19-tetramethyl-17
76. Clooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-o-(2,6-dideoxy-3-o-methyl-alpha-l-arabino-hexopyranosyl)-3-o-methyl-alpha-l-arabino-hexopyranoside
| Molecular Weight | 875.1 g/mol |
|---|---|
| Molecular Formula | C48H74O14 |
| XLogP3 | 4.1 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 14 |
| Rotatable Bond Count | 8 |
| Exact Mass | 874.50785703 g/mol |
| Monoisotopic Mass | 874.50785703 g/mol |
| Topological Polar Surface Area | 170 Ų |
| Heavy Atom Count | 62 |
| Formal Charge | 0 |
| Complexity | 1680 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 20 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 3 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of rosacea
Antiparasitic Agents
Drugs used to treat or prevent parasitic infections. (See all compounds classified as Antiparasitic Agents.)
Insecticides
Pesticides designed to control insects that are harmful to man. The insects may be directly harmful, as those acting as disease vectors, or indirectly harmful, as destroyers of crops, food products, or textile fabrics. (See all compounds classified as Insecticides.)
D - Dermatologicals
D11 - Other dermatological preparations
D11A - Other dermatological preparations
D11AX - Other dermatologicals
D11AX22 - Ivermectin
P - Antiparasitic products, insecticides and repellents
P02 - Anthelmintics
P02C - Antinematodal agents
P02CF - Avermectines
P02CF01 - Ivermectin
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.
NDC Package Code : 10695-052
Start Marketing Date : 2019-09-23
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.
NDC Package Code : 10695-052
Start Marketing Date : 2019-03-11
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.
NDC Package Code : 10695-052
Start Marketing Date : 2019-03-11
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-02-08
Pay. Date : 2012-12-18
DMF Number : 21624
Submission : 2008-05-08
Status : Active
Type : II
Certificate Number : CEP 2025-175 - Rev 01
Issue Date : 2025-11-17
Type : Chemical
Substance Number : 1336
Status : Valid
Registration Number : 304MF10048
Registrant's Address : 46 Waisha Road, Jiaojiang District, Taizhou City, Zhejiang Province, P. R. China 318000
Initial Date of Registration : 2022-03-02
Latest Date of Registration :
NDC Package Code : 58623-0047
Start Marketing Date : 2014-10-24
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Ace Biopharm Co., Ltd.
Registration Date : 2025-02-21
Registration Number : 20250221-211-J-1776
Manufacturer Name : Zhejiang Hisun Pharmaceutical Co., Ltd.
Manufacturer Address : 56 Binhai Road, Jiaojiang District, Taizhou City, Zhejiang Province, People's Republic of China
VMF Number : 5553
Submission : 1995-12-14
Status : Active
Type : II

GDUFA
DMF Review : Reviewed
Rev. Date : 2013-01-09
Pay. Date : 2012-12-14
DMF Number : 21395
Submission : 2008-03-05
Status : Active
Type : II
Certificate Number : R1-CEP 1998-138 - Rev 05
Issue Date : 2020-02-28
Type : Chemical
Substance Number : 1336
Status : Valid
Registration Number : 221MF10281
Registrant's Address : Estrada Coronel Nicolau de Mesquita Taipa, Macau S. A. R. China
Initial Date of Registration : 2009-12-18
Latest Date of Registration :
NDC Package Code : 55018-221
Start Marketing Date : 2009-03-19
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : Reviewed
Rev. Date : 2022-04-06
Pay. Date : 2022-01-13
DMF Number : 36494
Submission : 2021-11-15
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17673
Submission : 2004-07-18
Status : Inactive
Type : II

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 12755
Submission : 1997-11-21
Status : Inactive
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 17673
Submission : 2004-07-18
Status : Inactive
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2013-01-09
Pay. Date : 2012-12-14
DMF Number : 21395
Submission : 2008-03-05
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2022-04-06
Pay. Date : 2022-01-13
DMF Number : 36494
Submission : 2021-11-15
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2014-02-08
Pay. Date : 2012-12-18
DMF Number : 21624
Submission : 2008-05-08
Status : Active
Type : II

USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38553
Submission : 2023-06-27
Status : Active
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13037
Submission : 1998-06-15
Status : Inactive
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 12755
Submission : 1997-11-21
Status : Inactive
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : CEP 2021-382 - Rev 00
Status : Valid
Issue Date : 2024-08-02
Type : Chemical
Substance Number : 1336

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R0-CEP 2021-477 - Rev 00
Status : Valid
Issue Date : 2022-04-22
Type : Chemical
Substance Number : 1336

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R1-CEP 2008-104 - Rev 02
Status : Withdrawn by Holder
Issue Date : 2020-06-08
Type : Chemical
Substance Number : 1336

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R1-CEP 1998-138 - Rev 05
Status : Valid
Issue Date : 2020-02-28
Type : Chemical
Substance Number : 1336

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R1-CEP 2001-146 - Rev 01
Status : Valid
Issue Date : 2008-11-27
Type : Chemical
Substance Number : 1336

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R1-CEP 2004-070 - Rev 01
Status : Valid
Issue Date : 2011-08-02
Type : Chemical
Substance Number : 1336

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R0-CEP 2010-123 - Rev 00
Status : Expired
Issue Date : 2011-10-25
Type : Chemical
Substance Number : 1336

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R1-CEP 2001-077 - Rev 01
Status : Valid
Issue Date : 2017-10-16
Type : Chemical
Substance Number : 1336

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R0-CEP 2006-008 - Rev 01
Status : Expired
Issue Date : 2010-06-17
Type : Chemical
Substance Number : 1336

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : CEP 2025-175 - Rev 01
Status : Valid
Issue Date : 2025-11-17
Type : Chemical
Substance Number : 1336

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] Registration Number : 304MF10006
Registrant's Address : Estrada Coronel Nicolau de Mesquita Taipa, Macau S. A. R. China
Initial Date of Registration : 2022-01-11
Latest Date of Registration : 2022-01-11

Registration Number : 221MF10281
Registrant's Address : Estrada Coronel Nicolau de Mesquita Taipa, Macau S. A. R. China
Initial Date of Registration : 2009-12-18
Latest Date of Registration : 2025-08-21

Registration Number : 304MF10048
Registrant's Address : 46 Waisha Road, Jiaojiang District, Taizhou City, Zhejiang Province, P. R. China 3180...
Initial Date of Registration : 2022-03-02
Latest Date of Registration : 2022-03-02

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Registrant Name : Ace Biopharm Co., Ltd.
Registration Date : 2025-02-21
Registration Number : 20250221-211-J-1776
Manufacturer Name : Zhejiang Hisun Pharmaceutica...
Manufacturer Address : 56 Binhai Road, Jiaojiang District, Taizhou City, Zhejiang Province, People's Republi...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.
NDC Package Code : 10695-052
Start Marketing Date : 2019-09-23
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.
NDC Package Code : 10695-052
Start Marketing Date : 2019-03-11
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.
NDC Package Code : 10695-052
Start Marketing Date : 2019-03-11
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 73377-144
Start Marketing Date : 2021-08-13
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...

NDC Package Code : 77382-0100
Start Marketing Date : 1998-10-08
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 49885-0006
Start Marketing Date : 2019-09-13
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 55018-221
Start Marketing Date : 2009-03-19
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 60592-316
Start Marketing Date : 2019-12-19
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT

NDC Package Code : 85411-118
Start Marketing Date : 2025-06-18
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
NDC Package Code : 68171-0001
Start Marketing Date : 2007-12-21
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]VMF Number : 5672
Submission : 1999-11-22
Status : Inactive
Type : II

VMF Number : 5906
Submission : 2007-09-20
Status : Inactive
Type : II

VMF Number : 6221
Submission : 2018-01-16
Status : Active
Type : II

VMF Number : 5914
Submission : 2008-01-15
Status : Inactive
Type : II

VMF Number : 5476
Submission : 1993-10-22
Status : Inactive
Type : II

VMF Number : 5774
Submission : 2003-06-10
Status : Active
Type : II

VMF Number : 5720
Submission : 2001-05-11
Status : Active
Type : II

VMF Number : 5576
Submission : 1996-11-20
Status : Inactive
Type : II

VMF Number : 5797
Submission : 2004-03-24
Status : Inactive
Type : II

VMF Number : 5553
Submission : 1995-12-14
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for pharmaceutical and biotech industries. LGM also operates as a full-service CDMO, offering formulat...
About the Company : Jai Radhe Sales, founded in 1999, is a global distributor specializing in high-quality pharmaceutical ingredients from India. It offers complete sourcing solutions, technical and r...
Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.
About the Company : Willow Birch Pharma, Inc. is a premier supplier of bulk APIs to North American Compounding Pharmacies, sourcing from FDA registered and GMP manufacturers. With licenses in all 50 s...
About the Company : Alfa Chemistry offers an extensive catalog of building blocks, reagents, catalysts, reference materials, and research chemicals in a wide range of applications. We also provide ana...

About the Company : Hebei Veyong Pharmaceutical Co., Ltd, was established in 2002 and located in Economic and Technological Development Zone in Shijiazhuang. It is a large veterinary enterprise with G...

About the Company : HENGDIAN GROUP was established in 1975, till now it has become a transnational,conglomerate group and been one of the largest private-owned enterprises in China. The Pharmaceutical...

About the Company : HENGDIAN GROUP was established in 1975, till now it has become a transnational,conglomerate group and been one of the largest private-owned enterprises in China. The Pharmaceutical...

About the Company : Hovione is an international company with over 60 years of experience as a Contract Development and Manufacturing Organization (CDMO) with a fully integrated offering of services fo...

About the Company : Consistent growth and sustainability is a multidimensional aspiration for all at Macleods, we remained focused on providing quality and affordable medicines to billions of ailing p...

About the Company : QILU PHARMACEUTICAL GROUP , Shandong Qilu King-Phar Pharmaceutical Co., Ltd. is the location of our fermentation processing plant , one of 8 sites specializing in production of a...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Stromectol-Generic (ivermectin) is a glutamate-gated chloride channel modulator, small molecule drug candidate, which is indicated for the treatment of patients with strongyloidiasis & onchocerciasis.
Lead Product(s): Ivermectin,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Stromectol-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Senores Pharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 26, 2024
Lead Product(s) : Ivermectin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Senores Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Dr. Reddy's Laboratories and Senores Pharmaceuticals Launch Ivermectin Tablets in US
Details : Stromectol-Generic (ivermectin) is a glutamate-gated chloride channel modulator, small molecule drug candidate, which is indicated for the treatment of patients with strongyloidiasis & onchocerciasis.
Product Name : Stromectol-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 26, 2024
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Ivermectin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Rosacea.
Lead Product(s): Ivermectin,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 16, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ivermectin,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Ivermectin 1% Cream and Soolantra (Ivermectin) 10 mg/g Cream
Details : Ivermectin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Rosacea.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 16, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The mdc-STM is an investigational three-month active injectable formulation of ivermectin using Medincell’s BEPO technology to fight malaria transmission.
Lead Product(s): Ivermectin,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: mdc-STM
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: Unitaid
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Funding April 08, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ivermectin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Unitaid
Deal Size : $6.0 million
Deal Type : Funding
Unitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria
Details : The mdc-STM is an investigational three-month active injectable formulation of ivermectin using Medincell’s BEPO technology to fight malaria transmission.
Product Name : mdc-STM
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 08, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Ivermectin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of COVID-19.
Lead Product(s): Ivermectin,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 15, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ivermectin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Ivermectin to Prevent SARS-CoV-2 (COVID-19) Hospitalisation in Subjects Over 50
Details : Ivermectin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 15, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The SAIVE study was conducted to support mdc-TTG program, whose objective is to provide prevention of Covid-19 infection for weeks or months with a single injection of a long-acting formulation of ivermectin based on MedinCell’s proprietary technology, BEPO®.
Lead Product(s): Ivermectin,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: mdc-STM
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 05, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ivermectin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The SAIVE study was conducted to support mdc-TTG program, whose objective is to provide prevention of Covid-19 infection for weeks or months with a single injection of a long-acting formulation of ivermectin based on MedinCell’s proprietary technology,...
Product Name : mdc-STM
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 05, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
This non-exclusive licence agreement, will enable MPP to support the identification of suitable partners for the development and commercialisation of mdc-STM, an injectable formulation of ivermectin with a three-month action-duration.
Lead Product(s): Ivermectin,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: mdc-STM
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: The Medicines Patent Pool
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 13, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ivermectin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : The Medicines Patent Pool
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : This non-exclusive licence agreement, will enable MPP to support the identification of suitable partners for the development and commercialisation of mdc-STM, an injectable formulation of ivermectin with a three-month action-duration.
Product Name : mdc-STM
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 13, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Ivermectin is a Food and Drug Administration (FDA)-approved antiparasitic drug used to treat several neglected tropical diseases, including onchocerciasis, helminthiases, and scabies.
Lead Product(s): Ivermectin,Inapplicable
Therapeutic Area: Dermatology Brand Name: Ivermectin-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 04, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ivermectin,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Gets USFDA Nod for Ivermectin Cream
Details : Ivermectin is a Food and Drug Administration (FDA)-approved antiparasitic drug used to treat several neglected tropical diseases, including onchocerciasis, helminthiases, and scabies.
Product Name : Ivermectin-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 04, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Lyndra’s investigational long-acting oral biweekly ivermectin (LYN-163), enabled by Lyndra’s LYNX™ drug delivery platform, is being studied as a tool in the fight to eradicate malaria.
Lead Product(s): Ivermectin,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 09, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ivermectin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lyndra’s investigational long-acting oral biweekly ivermectin (LYN-163), enabled by Lyndra’s LYNX™ drug delivery platform, is being studied as a tool in the fight to eradicate malaria.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 09, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Ivermectin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Breast Neoplasms.
Lead Product(s): Ivermectin,Balstilmab,Pembrolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Yuan Yuan
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 08, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ivermectin,Balstilmab,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Yuan Yuan
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ivermectin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 08, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Ivermectin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.
Lead Product(s): Ivermectin,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Violaine Desort-Hénin, DVM
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 31, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ivermectin,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Violaine Desort-Hénin, DVM
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate the Efficacy and Safety of Ivermectin in COVID-19 Prevention
Details : Ivermectin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 31, 2022

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Dosage Form : Tablet
Grade : Oral
Dosage Form : Cream / Lotion / Ointment
Grade : Topical, Parenteral
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dosage Form : Tablet
Grade : Oral
Application : Controlled & Modified Release
Excipient Details : ACTILLETS are microcrystalline cellulose spheres developed using advanced drug delivery technology to enable effective loading & coating of particles.
Pharmacopoeia Ref : NA
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose Excipients
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Application : Taste Masking
Excipient Details : CS90 is a directly compressible calcium carbonate with starch used for chewable tablets due to its smooth mouthfeel and creamy texture.
Pharmacopoeia Ref : NA
Technical Specs : PSD D50: 150-175 µm, Tapped Density: 0.85
Ingredient(s) : Calcium Carbonate Excipient
Dosage Form : Tablet
Grade : Oral
Application : Direct Compression
Excipient Details : DC SIM 100 is a directly compressible simethicone powder used for antacid and anti-gas tablets.
Dosage Form : Tablet
Grade : Oral
Application : Taste Masking
Excipient Details : MS90 is a directly compressible magnesium hydroxide with starch used for chewable tablets due to its smooth mouthfeel and creamy texture.
Pharmacopoeia Ref : NA
Technical Specs : PSD D50: 150-170 µm, Tapped Density: 0.80
Ingredient(s) : Magnesium Hydroxide Excipient
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dosage Form : Tablet
Grade : Oral
Application : Fillers, Diluents & Binders
Excipient Details : TABCELL serves as an excellent excipient for solid dosage forms, providing numerous advantages for tablet formulations.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose Excipients
Dosage Form : Tablet
Grade : Oral
Application : Lubricants & Glidants
Excipient Details : TABLUBE is one of the oldest and most widely used lubricants for tablet, capsules and other solid dosage forms.
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Magnesium Stearate
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
50
PharmaCompass offers a list of Ivermectin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ivermectin manufacturer or Ivermectin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ivermectin manufacturer or Ivermectin supplier.
PharmaCompass also assists you with knowing the Ivermectin API Price utilized in the formulation of products. Ivermectin API Price is not always fixed or binding as the Ivermectin Price is obtained through a variety of data sources. The Ivermectin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Merck Brand of Ivermectin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Merck Brand of Ivermectin, including repackagers and relabelers. The FDA regulates Merck Brand of Ivermectin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Merck Brand of Ivermectin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Merck Brand of Ivermectin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Merck Brand of Ivermectin supplier is an individual or a company that provides Merck Brand of Ivermectin active pharmaceutical ingredient (API) or Merck Brand of Ivermectin finished formulations upon request. The Merck Brand of Ivermectin suppliers may include Merck Brand of Ivermectin API manufacturers, exporters, distributors and traders.
click here to find a list of Merck Brand of Ivermectin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Merck Brand of Ivermectin DMF (Drug Master File) is a document detailing the whole manufacturing process of Merck Brand of Ivermectin active pharmaceutical ingredient (API) in detail. Different forms of Merck Brand of Ivermectin DMFs exist exist since differing nations have different regulations, such as Merck Brand of Ivermectin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Merck Brand of Ivermectin DMF submitted to regulatory agencies in the US is known as a USDMF. Merck Brand of Ivermectin USDMF includes data on Merck Brand of Ivermectin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Merck Brand of Ivermectin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Merck Brand of Ivermectin suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Merck Brand of Ivermectin Drug Master File in Japan (Merck Brand of Ivermectin JDMF) empowers Merck Brand of Ivermectin API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Merck Brand of Ivermectin JDMF during the approval evaluation for pharmaceutical products. At the time of Merck Brand of Ivermectin JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Merck Brand of Ivermectin suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Merck Brand of Ivermectin Drug Master File in Korea (Merck Brand of Ivermectin KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Merck Brand of Ivermectin. The MFDS reviews the Merck Brand of Ivermectin KDMF as part of the drug registration process and uses the information provided in the Merck Brand of Ivermectin KDMF to evaluate the safety and efficacy of the drug.
After submitting a Merck Brand of Ivermectin KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Merck Brand of Ivermectin API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Merck Brand of Ivermectin suppliers with KDMF on PharmaCompass.
A Merck Brand of Ivermectin CEP of the European Pharmacopoeia monograph is often referred to as a Merck Brand of Ivermectin Certificate of Suitability (COS). The purpose of a Merck Brand of Ivermectin CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Merck Brand of Ivermectin EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Merck Brand of Ivermectin to their clients by showing that a Merck Brand of Ivermectin CEP has been issued for it. The manufacturer submits a Merck Brand of Ivermectin CEP (COS) as part of the market authorization procedure, and it takes on the role of a Merck Brand of Ivermectin CEP holder for the record. Additionally, the data presented in the Merck Brand of Ivermectin CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Merck Brand of Ivermectin DMF.
A Merck Brand of Ivermectin CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Merck Brand of Ivermectin CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Merck Brand of Ivermectin suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Merck Brand of Ivermectin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Merck Brand of Ivermectin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Merck Brand of Ivermectin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Merck Brand of Ivermectin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Merck Brand of Ivermectin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Merck Brand of Ivermectin suppliers with NDC on PharmaCompass.
Merck Brand of Ivermectin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Merck Brand of Ivermectin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Merck Brand of Ivermectin GMP manufacturer or Merck Brand of Ivermectin GMP API supplier for your needs.
A Merck Brand of Ivermectin CoA (Certificate of Analysis) is a formal document that attests to Merck Brand of Ivermectin's compliance with Merck Brand of Ivermectin specifications and serves as a tool for batch-level quality control.
Merck Brand of Ivermectin CoA mostly includes findings from lab analyses of a specific batch. For each Merck Brand of Ivermectin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Merck Brand of Ivermectin may be tested according to a variety of international standards, such as European Pharmacopoeia (Merck Brand of Ivermectin EP), Merck Brand of Ivermectin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Merck Brand of Ivermectin USP).